Compare iShares MSCI China ETF (MCHI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI China ETF trades at $52.41 (market cap $5.94B), while Zimmer Biomet Holdings Inc trades at $88.93 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.9× iShares MSCI China ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MCHI | ZBH | |
|---|---|---|
Market Cap | $5.94B | $16.95B |
Volume | 1,575,471 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $103.98 |
52-Week Low | $50.48 | $79.58 |
Typical Hold Time | 63 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.45, up 1.57% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with corporate profits surging 26% in Q2 2026 while exports face global pushback. Institutional activity shows conflicting positions with Empowered Funds acquiring shares while Acima Private Wealth reduced holdings.
The outlook remains cautious given China's macroeconomic pressures and trade tensions. Investment opportunity exists in the significant discount to historical valuations, but risks include potential export controls, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
